A big STEP for treatment of heart failure with preserved ejection fraction

Subodh Verma; Barry A. Borlaug; Javed Butler; Melanie J. Davies; Dalane W. Kitzman; Mark C. Petrie; Sanjiv J. Shah; Nitish K. Dhingra; Mikhail N. Kosiborod

doi:10.1016/j.cmet.2023.08.003

A big STEP for treatment of heart failure with preserved ejection fraction

Subodh Verma, Barry A. Borlaug, Javed Butler, Melanie J. Davies, Dalane W. Kitzman, Mark C. Petrie, Sanjiv J. Shah, Nitish K. Dhingra, Mikhail N. Kosiborod

Cardiovascular Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the STEP-HFpEF trial, 2.4 mg semaglutide produced marked improvements in heart failure-related symptoms, physical limitations, and exercise function, and reduced inflammation and body weight in individuals with obesity HFpEF phenotype. These data usher in a new paradigm of targeting obesity as a therapeutic strategy in HFpEF.

Original language	English (US)
Pages (from-to)	1681-1687
Number of pages	7
Journal	Cell Metabolism
Volume	35
Issue number	10
DOIs	https://doi.org/10.1016/j.cmet.2023.08.003
State	Published - Oct 3 2023

ASJC Scopus subject areas

Physiology
Molecular Biology
Cell Biology

Access to Document

10.1016/j.cmet.2023.08.003

Cite this

@article{fd31306397cb479287a1e5c5f7bfeb91,

title = "A big STEP for treatment of heart failure with preserved ejection fraction",

abstract = "In the STEP-HFpEF trial, 2.4 mg semaglutide produced marked improvements in heart failure-related symptoms, physical limitations, and exercise function, and reduced inflammation and body weight in individuals with obesity HFpEF phenotype. These data usher in a new paradigm of targeting obesity as a therapeutic strategy in HFpEF.",

author = "Subodh Verma and Borlaug, {Barry A.} and Javed Butler and Davies, {Melanie J.} and Kitzman, {Dalane W.} and Petrie, {Mark C.} and Shah, {Sanjiv J.} and Dhingra, {Nitish K.} and Kosiborod, {Mikhail N.}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Inc.",

year = "2023",

month = oct,

day = "3",

doi = "10.1016/j.cmet.2023.08.003",

language = "English (US)",

volume = "35",

pages = "1681--1687",

journal = "Cell Metabolism",

issn = "1550-4131",

publisher = "Cell Press",

number = "10",

}

TY - JOUR

T1 - A big STEP for treatment of heart failure with preserved ejection fraction

AU - Verma, Subodh

AU - Borlaug, Barry A.

AU - Butler, Javed

AU - Davies, Melanie J.

AU - Kitzman, Dalane W.

AU - Petrie, Mark C.

AU - Shah, Sanjiv J.

AU - Dhingra, Nitish K.

AU - Kosiborod, Mikhail N.

PY - 2023/10/3

Y1 - 2023/10/3

N2 - In the STEP-HFpEF trial, 2.4 mg semaglutide produced marked improvements in heart failure-related symptoms, physical limitations, and exercise function, and reduced inflammation and body weight in individuals with obesity HFpEF phenotype. These data usher in a new paradigm of targeting obesity as a therapeutic strategy in HFpEF.

AB - In the STEP-HFpEF trial, 2.4 mg semaglutide produced marked improvements in heart failure-related symptoms, physical limitations, and exercise function, and reduced inflammation and body weight in individuals with obesity HFpEF phenotype. These data usher in a new paradigm of targeting obesity as a therapeutic strategy in HFpEF.

UR - http://www.scopus.com/inward/record.url?scp=85170548094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85170548094&partnerID=8YFLogxK

U2 - 10.1016/j.cmet.2023.08.003

DO - 10.1016/j.cmet.2023.08.003

M3 - Comment/debate

C2 - 37643614

AN - SCOPUS:85170548094

SN - 1550-4131

VL - 35

SP - 1681

EP - 1687

JO - Cell Metabolism

JF - Cell Metabolism

IS - 10

ER -

A big STEP for treatment of heart failure with preserved ejection fraction

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this